Richard S. Gunasekera

Dr. Richard S. Gunasekera


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
TGThushara Galbadage
Thushara Galbadage
BPBrent M. Peterson
Brent M. Peterson
JAJoseph Awada
Joseph Awada
ABAlison S. Buck
Alison S. Buck
DRDanny A. Ramirez
Danny A. Ramirez
RGRichard S. Gunasekera
Richard S. Gunasekera
To successfully mitigate the extraordinary devastation caused by the Coronavirus disease 2019 (COVID-19) pandemic, it is crucial to identify important risk factors for this disease. One such neglected health determinant is the sex of the patient. This is an essential clinical characteristic, as it can factor into a patient's clinical management and preventative measures. Some clinical studies have shown disparities in the proportion between males and females that have more severe clinical outcomes or, subsequently, die from this disease. However, this association has not been unequivocally established. Thus, the purpose of this investigation was to examine the association between male sex and COVID-19 severity. We systematically reviewed the literature, identified studies that matched predetermined selection criteria, and performed a meta-analysis to evaluate the proportion of males among four disease severity categories. Appropriate assessment strategies were implemented to assess and minimize potential biases. The results of this meta-analysis indicated that males constituted a significantly higher proportion of those who had adverse clinical outcomes and died from COVID-19. As the coronavirus spread from the East to the West, male sex remained a consistent risk factor. Our results support the establishment of the male sex as an important risk factor for this disease. Early identification and appropriate medical care for males with lab-confirmed COVID-19 may substantially change the course of clinical prognosis, resulting in greater numbers of lives saved.

24 April 2020 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
TGThushara Galbadage
Thushara Galbadage
BPBrent M. Peterson
Brent M. Peterson
RGRichard S. Gunasekera
Richard S. Gunasekera
Does COVID-19 Spread Through Droplets Alone?

9 December 2019 in ACS Nano
Verified
Journal Article
Open access
TGThushara Galbadage
Thushara Galbadage
DLDongdong Liu
Dongdong Liu
LALawrence B. Alemany
Lawrence B. Alemany
RPRobert Pal
Robert Pal
JTJames Tour
James Tour
JCJeffrey D Cirillo
Jeffrey D Cirillo
Multidrug-resistance in pathogenic bacteria is an increasing problem in patient care and public health. Molecular nanomachines (MNM) have the ability to open cell membranes using nanomechanical action. We hypothesized that MNM could be used as antibacterial agents by drilling into bacterial cell walls and increasing susceptibility of drug resistant bacteria to recently ineffective antibiotics. We exposed extensively drug resistant K. pneumoniae to light-activated MNM and found that MNM increase susceptibility to meropenem. MNM with meropenem can effectively kill K. pneumoniae that are considered meropenem resistant. We examined the mechanisms of MNM action using permeability assays and transmission electron microscopy, finding that MNM disrupt the cell wall of extensively drug resistant K. pneumoniae, exposing the bacteria to meropenem. These observations suggest that MNM could be used to make conventional antibiotics more efficacious against multidrug-resistant pathogens.

24 February 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
RGRichard S. Gunasekera
Richard S. Gunasekera
TGThushara Galbadage
Thushara Galbadage
CACiceron Ayala-Orozco
Ciceron Ayala-Orozco
DLDongdong Liu
Dongdong Liu
VGVictor García-López
Victor García-López
JTJames Tour
James Tour
Light-activated molecular nanomachines (MNMs) can be used to drill holes into prokaryotic (bacterial) cell walls and the membrane of eukaryotic cells, including mammalian cancer cells, by their fast rotational movement, leading to cell death. We examined how these MNMs function in multicellular organisms and investigated their use for treatment and eradication of specific diseases by causing damage to certain tissues and small organisms. Three model eukaryotic species, Caenorhabditis elegans, Daphnia pulex, and Mus musculus (mouse), were evaluated. These organisms were exposed to light-activated fast-rotating MNMs and their physiological and pathological changes were studied in detail. Slow rotating MNMs were used to control for the effects of rotation rate. We demonstrate that fast-rotating MNMs caused depigmentation and 70% mortality in C. elegans while reducing the movement as well as heart rate and causing tissue damage in Daphnia. Topically applied light-activated MNMs on mouse skin caused ulceration and microlesions in the epithelial tissue, allowing MNMs to localize into deeper epidermal tissue. Overall, this study shows that the nanomechanical action of light-activated MNMs is effective against multicellular organisms, disrupting cell membranes and damaging tissue in vivo. Customized MNMs that target specific tissues for therapy combined with spatial and temporal control could have broad clinical applications in a variety of benign and malignant disease states including treatment of cancer, parasites, bacteria, and diseased tissues.

3 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SMShaveen De Mel
Shaveen De Mel
JGJuliana Gruenler
Juliana Gruenler
LKLogan Khoury
Logan Khoury
AHAshton Heynes
Ashton Heynes
JFJulianne Fazekas
Julianne Fazekas
RARoss S. Anderson
Ross S. Anderson
The biosynthesis of silver nanoparticles has recently emerged as a promising approach in nanomedicine, particularly for targeted therapeutic applications. Green synthesized (plant-based) nanoparticles have been shown to offer enhanced reduction efficiency, greater bioavailability, and improved stability compared to synthetic nanoparticles. Here, we report the green synthesis of silver nanoparticles (AgNPs) using Magnolia alba leaf extract (MLE). The formation of these Magnolia-derived silver nanoparticles (MAgNPs) was verified through UV–Vis spectroscopy with a surface plasmon resonance peak at 440 nm, and further characterized by scanning electron microscopy, which showed that the MAgNPs have a mean diameter of 40 nm and a spherical morphology. MAgNPs exhibited significant antibacterial activity against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, methicillin-resistant and -sensitive Staphylococcus aureus, with a minimum inhibitory concentration of 0.00043 mg/mL and a minimum bactericidal concentration of 0.00043 mg/mL and 0.0017 mg/mL, respectively. Disc diffusion and plaque assays with MAgNPs demonstrated strong antifungal activity against Candida albicans, with a zone of inhibition of 14 mm, and antiviral activity against T7 bacteriophage (p = 0.0004). In vitro studies with HCT-116 human colon cancer cells, MAgNPs exhibited bi-phasic, dose-dependent inhibition of viability with a 20–40% reduction, surpassing the positive control Camptothecin. Antioxidant assays indicated that MAgNPs showed significantly higher antioxidant activity compared to MLE, with enhanced Total Flavonoid Content (p = 0.0066), Total Phenol Content (p = 0.0013), and Total Antioxidant Capacity (p = 0.0051). Additionally, MAgNPs showed efficient photocatalytic degradation of the azo bond in methyl orange within 30 min. To our knowledge, this is the first report on the biosynthesis of MAgNPs and their multifunctional properties, highlighting the promise of MAgNPs in biomedical and environmental fields. (Insert attached Graphical abstract)

8 December 2020 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
TGThushara Galbadage
Thushara Galbadage
BPBrent M. Peterson
Brent M. Peterson
JWJeffrey S. Wang
Jeffrey S. Wang
AJAvishka Jayasekara
Avishka Jayasekara
DRDanny A. Ramirez
Danny A. Ramirez
RGRichard S. Gunasekera
Richard S. Gunasekera
Clinical and epidemiological studies have identified male sex as an important risk factor for COVID-19 clinical outcomes and mortality. This raises the question as to how this risk factor can be addressed in the prognosis, clinical management, and the treatment of patients with Coronavirus disease 2019 (COVID-19). Currently, there are no guidelines or protocols to help alter the course of sex-specific COVID-19 prognosis, especially in severe disease presentations. This is partly due to the lack of research studies characterizing the differences in male vs. female host response to the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) infection and a lack of a well-rounded understanding of the molecular mechanisms involved. Here, we discuss three distinct but interconnected molecular-level differences in males and females that likely play an essential role in the COVID-19 prognosis. We review interactions of SARS-CoV-2 with host cell angiotensin-converting enzyme 2 (ACE2) in the viral entry between males vs. females and discuss the differential regulation of the renin-angiotensin system (RAS) between the two sexes. Next, we present immune response disparities and how immune function and endocrine regulation may render males increasingly vulnerable to severe COVID-19. We describe the interconnected roles of these three regulatory systems in males and females in response to SARS-CoV-2 infection. Finally, we highlight the clinical implications of these mechanisms to patients with COVID-19 and propose putative targeted therapies that can help reduce COVID-19 severity in those critically ill.